KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Tax Provisions (2017 - 2025)

Historic Tax Provisions for Sarepta Therapeutics (SRPT) over the last 9 years, with Q2 2025 value amounting to -$43.3 million.

  • Sarepta Therapeutics' Tax Provisions fell 70840.24% to -$43.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$22.8 million, marking a year-over-year decrease of 25135.85%. This contributed to the annual value of $25.8 million for FY2024, which is 6070.81% up from last year.
  • Sarepta Therapeutics' Tax Provisions amounted to -$43.3 million in Q2 2025, which was down 70840.24% from $12.9 million recorded in Q4 2024.
  • Sarepta Therapeutics' Tax Provisions' 5-year high stood at $12.9 million during Q4 2024, with a 5-year trough of -$43.3 million in Q2 2025.
  • Over the past 5 years, Sarepta Therapeutics' median Tax Provisions value was $1.3 million (recorded in 2022), while the average stood at $738058.8.
  • In the last 5 years, Sarepta Therapeutics' Tax Provisions plummeted by 187000.0% in 2021 and then skyrocketed by 919347.83% in 2022.
  • Sarepta Therapeutics' Tax Provisions (Quarter) stood at $92000.0 in 2021, then soared by 9193.48% to $8.5 million in 2022, then crashed by 160.3% to -$5.2 million in 2023, then surged by 351.03% to $12.9 million in 2024, then plummeted by 434.54% to -$43.3 million in 2025.
  • Its Tax Provisions was -$43.3 million in Q2 2025, compared to $12.9 million in Q4 2024 and $400000.0 in Q3 2024.